LifeSci Capital initiated coverage of Monte Rosa Therapeutics (GLUE) with an Outperform rating and $19 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks